Evaluates β-carotene nanoliposomes against prostate carcinoma, implying therapeutic potential for cancer treatment.
AIMS: This study evaluated β-carotene-loaded lecithin nanoliposomes as a prostate cancer nanoplatform and assessed whether B-cell lymphoma 2 (Bcl-2) modulation could explain their activity. MATERIALS AND METHODS: Neutral multilamellar vesicles were prepared by thin-film hydration and characterized by transmission electron microscopy (TEM), dynamic light scattering (DLS), zeta potential, differential scanning calorimetry (DSC), and Fourier-transform infrared spectroscopy (FTIR). PC-3 cells were assessed using MTT cytotoxicity, alkaline comet assay, Annexin V-fluorescein isothiocyanate/propidium iodide (Annexin V-FITC/PI) apoptosis analysis, and cell-cycle profiling. Docking, 100 ns molecular dynamics (MD), and molecular mechanics/generalized Born surface area (MM/GBSA) analyses examined β-carotene binding to Bcl-2. RESULTS AND CONCLUSION: Encapsulation efficiency exceeded 90%. Free β-carotene showed the lowest IC50 (13.50 µg/mL), followed by liposomal β-carotene (28.26 µg/mL) and empty liposomes (36.41 µg/mL). Liposomal β-carotene produced the strongest comet-assay DNA damage and G0/G1 arrest, whereas free β-carotene induced the highest total apoptosis. Simulations showed stable hydrophobic occupation of the Bcl-2 BH3/BH1 groove. β-Carotene liposomes modulate cytotoxic kinetics and genotoxic stress, supporting optimized carotenoid nanocarriers.
No takes yet. Share an insight, caveat, or question.
Khedr et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: